JP7619941B2 - Ｃｄ２５抗体 - Google Patents

Ｃｄ２５抗体 Download PDF

Info

Publication number
JP7619941B2
JP7619941B2 JP2021526461A JP2021526461A JP7619941B2 JP 7619941 B2 JP7619941 B2 JP 7619941B2 JP 2021526461 A JP2021526461 A JP 2021526461A JP 2021526461 A JP2021526461 A JP 2021526461A JP 7619941 B2 JP7619941 B2 JP 7619941B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
antibodies
presented
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507487A5 (enExample
JP2022507487A (ja
Inventor
リィ，ビン
ピー グリービング，マシュー
トゥ ジップ，プン
ルンドバーグ，マット
スリニバサン，モハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ibio Inc
Original Assignee
Ibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibio Inc filed Critical Ibio Inc
Publication of JP2022507487A publication Critical patent/JP2022507487A/ja
Publication of JP2022507487A5 publication Critical patent/JP2022507487A5/ja
Priority to JP2024158123A priority Critical patent/JP2024175003A/ja
Application granted granted Critical
Publication of JP7619941B2 publication Critical patent/JP7619941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021526461A 2018-11-14 2019-11-14 Ｃｄ２５抗体 Active JP7619941B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158123A JP2024175003A (ja) 2018-11-14 2024-09-12 Ｃｄ２５抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767405P 2018-11-14 2018-11-14
US62/767,405 2018-11-14
PCT/US2019/061552 WO2020102591A1 (en) 2018-11-14 2019-11-14 Cd25 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158123A Division JP2024175003A (ja) 2018-11-14 2024-09-12 Ｃｄ２５抗体

Publications (3)

Publication Number Publication Date
JP2022507487A JP2022507487A (ja) 2022-01-18
JP2022507487A5 JP2022507487A5 (enExample) 2023-06-14
JP7619941B2 true JP7619941B2 (ja) 2025-01-22

Family

ID=70730731

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526461A Active JP7619941B2 (ja) 2018-11-14 2019-11-14 Ｃｄ２５抗体
JP2024158123A Pending JP2024175003A (ja) 2018-11-14 2024-09-12 Ｃｄ２５抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158123A Pending JP2024175003A (ja) 2018-11-14 2024-09-12 Ｃｄ２５抗体

Country Status (6)

Country Link
US (2) US12215163B2 (enExample)
EP (1) EP3880227A4 (enExample)
JP (2) JP7619941B2 (enExample)
CN (1) CN113677359B (enExample)
CA (1) CA3120096A1 (enExample)
WO (1) WO2020102591A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
CN113646330A (zh) 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
BR112022001546A2 (pt) * 2019-07-30 2022-03-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
EP4084826A2 (en) * 2019-12-30 2022-11-09 University Of Louisville Research Foundation, Inc. Virus-like particle binding agents, related compositions, and related methods
JP7621481B2 (ja) * 2020-11-13 2025-01-24 アイバイオ， インク． Ｃｄ２５抗体
WO2022235295A1 (en) * 2021-05-07 2022-11-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CN115724971A (zh) * 2021-08-09 2023-03-03 南京诺艾新生物技术有限公司 重组抗人cd25抗体及其应用
JP2024534053A (ja) * 2021-08-25 2024-09-18 アイバイオ， インク． 抗ｃｄ２５抗体
WO2023129870A2 (en) * 2021-12-29 2023-07-06 Staidson Biopharma Inc. ANTIBODIES SPECIFICALLY RECOGNIZING C5aR1 AND USES THEREOF
US20250154268A1 (en) * 2022-01-17 2025-05-15 Nona Biosciences (Suzhou) Co., Ltd. Antibody targeting cd25, and preparation method therefor and use thereof
AU2023298151A1 (en) 2022-07-01 2025-01-02 Neurogene Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
TW202509067A (zh) * 2023-04-11 2025-03-01 大陸商蘇州創勝醫藥集團有限公司 抗ｃｄ２５抗體及其用途
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117050165B (zh) * 2023-08-14 2025-03-25 三优生物医药(上海)有限公司 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
CN118063607B (zh) * 2024-03-16 2026-08-07 珠海市丽珠单抗生物技术有限公司 抗犬il-31抗体及其用途
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN119331099B (zh) * 2024-11-06 2025-12-16 郑州伊美诺生物技术有限公司 抗嗜酸性粒细胞过氧化物酶的单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018167104A1 (en) 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295471B2 (en) * 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
CN107129524B (zh) * 2007-09-25 2023-11-21 田园温室气体研究有限公司 用于抑制微生物细胞的疫苗和疫苗组分
WO2011051327A2 (en) * 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10377815B2 (en) * 2015-05-05 2019-08-13 Albert Einstein College Of Medicine Bispecific antibodies and fusion proteins that bind to EBOV and NPC1
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
EA201900443A1 (ru) 2017-04-18 2020-03-06 Р-Фарм Оверсиз Инк. Антитело к pd-l1 и его применение
CN113646330A (zh) 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018167104A1 (en) 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology，2017年，Vol.8, Article 1782，pp.1-21

Also Published As

Publication number Publication date
US12215163B2 (en) 2025-02-04
US20230220102A1 (en) 2023-07-13
US20250122301A1 (en) 2025-04-17
CN113677359B (zh) 2026-07-24
JP2022507487A (ja) 2022-01-18
EP3880227A4 (en) 2022-11-09
EP3880227A1 (en) 2021-09-22
JP2024175003A (ja) 2024-12-17
WO2020102591A1 (en) 2020-05-22
CA3120096A1 (en) 2020-05-22
CN113677359A (zh) 2021-11-19

Similar Documents

Publication Publication Date Title
JP2024175003A (ja) Ｃｄ２５抗体
JP7621481B2 (ja) Ｃｄ２５抗体
US11292836B2 (en) Anti-CD47 antibodies and uses thereof
JP2024522360A (ja) 抗ｃｃｒ８抗体及びその使用
JP2022141693A (ja) インターロイキン２に結合する抗体およびその使用
TW202110882A (zh) 能結合胸腺基質淋巴細胞生成素的抗體及其應用
US20250179172A1 (en) Cd5 antibody and use thereof
JP2023532234A (ja) 抗ｃｄ７３抗体とその用途
EP3741777A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW201414747A (zh) Ｉｌ－１８結合分子
CN113980129A (zh) 一组il-11单克隆抗体及其医药用途
US11351251B2 (en) Anti-PD-L1-anti-TIM-3 bispecific antibodies
CN115038718A (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
KR102602564B1 (ko) 인터루킨-6의 인간 수용체에 결합가능한 항체 또는 항원 결합성 단편
JP2025157456A (ja) Ｃｄ４７に対する単一ドメイン抗体及びその用途
TW202600594A (zh) 結合構築體(一)
CN114616245B (zh) 一种抗cd38的抗体及其用途
HK40063825A (en) Cd25 antibodies
TW202602922A (zh) 結合構築體(二)
CN118871115A (zh) Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途
CN119552247A (zh) 抗cd25抗体及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20221111

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250109

R150 Certificate of patent or registration of utility model

Ref document number: 7619941

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150